Coherus Reports 75% Tagmokitug Response Rate in First-Line ESCC
Coherus Oncology reported a 75% confirmed response rate among evaluable first-line ESCC patients, rising to 89% after the data cutoff. The company plans to expand the cohort.
Coherus Oncology reported interim tagmokitug data showing a 75% confirmed response rate in evaluable first-line ESCC patients, rising to 89% after the data cutoff.Key Highlights:Original SEC Filing: Coherus Oncology, Inc. [ CHRS ] - 8-K - Oct. 29, 2026This is an AI-powered summary. It may contain i…